Devic’s Syndrome Treatment Market By Type Of Drugs (Eculizumab, Methylprednisolone, Azathioprine, Mycophenolate Mofetil, Rituximab) – Growth, Future Prospects, And Competitive Analysis, 2019 – 2027

Industry Outlook

Devic’s syndrome (neuromyelitis optica) treatment accounted for a market value of US$ 156.8 million in 2018 and is projected to grow at a CAGR of 12.0% during the forecast period from 2019 to 2027. Devic’s disease, or neuromyelitis optics, is an autoimmune disease in which antibodies and immune system cells mainly damage the optic nerves and the spinal cord but, in a few cases, also affect the brain. The injury to the optical nerves leads to inflammation and soreness, leading to vision loss and pain; the injury to the spinal cord leads to paralysis in the arms or legs, loss of sensation, and problems with bladder and bowel function. The key factors responsible for the growth of the global Devic’s syndrome treatment market are rising awareness and prevalence related to orphan diseases, the recent launch of the first-target-specific drug Soliris (Eculizumab), and a strong drug pipeline expected to provide significant growth in the market.

Soliris (eculizumab) will aid the significant growth of the Devic’s Syndrome treatment market throughout the forecast period.

Soliris (eculizumab) is a terminal complement inhibitor owned by Alexion. Soliris works by specifically preventing the activation of particular proteins in the complement system (C5a and C5b), which play a role in the treatment of Devic’s syndrome. Patients suffering from Devic’s syndrome possess AQP4 antibodies, and the body’s immune system can turn against itself to produce autoantibodies against AQP4. Activation of anti-AQP4 autoantibodies leads to damage to vital cells in the CNS, assisting further demyelination and the death of neurons, primarily in the optic nerve and spinal cord. There are three promising molecules in the Devic’s syndrome treatment pipeline, such as natalizumab (Phase 3; Hoffmann-La Roche/Chugai Pharmaceutical), MEDI-551 (Phase 2/3; MedImmune LLC), and RC18 (Phase 3; RemeGen, Ltd.). Chugai Pharmaceutical launched Phase 2 results related to Satralizumab on October 15, 2018; it is an investigational humanized anti-IL-6 receptor recycling monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).

North America dominated the overall global market specifically due to recent drug approvals, promising drugs in the pipeline, and a developed diagnostic landscape.

In 2018, North America dominated the market and was anticipated to retain its position throughout the forecast period due to high awareness related to orphan diseases, rising requirements for target-specific molecules to treat Devic’s Syndrome, and easy adaptability and accessibility for newly launched drugs. According to the National Multiple Sclerosis Society, there are around 4,000 people suffering from Devic’s syndrome in the United States, with a majority of women. Asia Pacific will grow during the forecast period from 2019 to 2027 due to increasing awareness related to Devic’s Syndrome, which will assist in the rise in diagnosis and treatment rates among patients suffering from rare diseases.

Historical and Forecast Period

The Devic’s Syndrome treatment market was analyzed considering current market trends for the base year of 2018, and based on future trends, CAGRs were calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

This report comprises in-depth information related to the Devic’s Syndrome treatment market, along with major factors affecting or assisting the market, such as opportunities, drivers, and restraints. A descriptive analysis covering market drivers, challenges, and opportunities is provided specifically for country-level and regional segmentation. This report covered detailed information related to the global Devic’s syndrome treatment market, segmented based on drug type and geography. The report also includes a pipeline analysis of upcoming drugs and a competitive analysis of the major companies present in the Devic’s Syndrome treatment market, including detailed data related to the competitive landscape of the market and the recent market strategies and product pipeline.

The major companies involved in the Devic’s Syndrome treatment industry were studied based on financial data, product portfolios, current press releases, and key market strategies. This report also covers attractive investment propositions analyzed based on an exclusive geographical PESTEL analysis. Major companies included in the report are Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidiary of Pfizer), Mylan Pharmaceuticals, Inc., Chugai Pharmaceutical, MedImmune LLC, and RemeGen, Ltd., among others.

Key questions are answered in this report.

• Which is the most desired drug used to manage and treat Devic’s syndrome, and why?
• What are the recent market strategies followed by the key companies and the competitive landscape of the Devic’s syndrome treatment market?
• Which are the current and future key geographical markets (regions and countries) in Devic’s syndrome treatment?
• Which is the fastest and largest growing Devic’s syndrome treatment segment globally?
• What are the drivers, restraints, and opportunities in the Devic’s syndrome treatment market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global DST Market Portraiture
2.2. Global DST Market, by Type of Drug, 2018 (US$ Mn)
2.3. Global DST Market, by Geography, 2018 Vs 2027 (Value %)

Chapter 3. Global Devic’s Syndrome Treatment (DST) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2018

Chapter 4. Global Devic’s Syndrome Treatment (DST) Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
4.1. Overview
4.2. Eculizumab
4.3. Methylprednisolone
4.4. Azathioprine
4.5. Mycophenolate Mofetil
4.6. Rituximab

Chapter 5. Global Devic’s Syndrome Treatment (DST) Market, Pipeline Analysis
5.1. Overview
5.2. Satralizumab – Phase III (Hoffmann-La Roche/ Chugai Pharmaceutical)
5.3. MEDI-551 – Phase II/III (MedImmune LLC)
5.4. RC18 – Phase III (RemeGen, Ltd.)

Chapter 6. Global Devic’s Syndrome Treatment (DST) Market, by Geography, 2017 – 2027 (US$ Mn)
6.1. Overview
6.2. North America DST Market Analysis, 2017 – 2027
6.2.1. North America DST Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.2.2. North America DST Market, by Country, 2017 – 2027 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe DST Market Analysis, 2017 – 2027
6.3.1. Europe DST Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.3.2. Europe DST Market, by Country, 2017 – 2027 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific DST Market Analysis, 2017 – 2027
6.4.1. Asia Pacific DST Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.4.2. Asia Pacific DST Market, by Country, 2017 – 2027 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Rest of APAC
6.5. Latin America DST Market Analysis, 2017 – 2027
6.5.1. Latin America DST Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.5.2. Latin America DST Market, by Country, 2017 – 2027 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) DST Market Analysis, 2017 – 2027
6.6.1. Middle East & Africa DST Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.6.2. MEA DST Market, by Region, 2017 – 2027 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Alexion Pharmaceuticals, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Teva Pharmaceuticals
7.3. Fresenius Kabi AG
7.4. Pharmacia & Upjohn (a subsidary of Pfizer)
7.5. Lupin Ltd.
7.6. Sagent Pharmaceuticals, Inc.
7.7. Zydus Pharmaceuticals, Inc.
7.8. Sandoz Inc. (a subsidiary of Novartis)
7.9. Alkem Laboratories Ltd.
7.10. Mylan Pharmaceuticals, Inc.
7.11. Hoffmann-La Roche/ Chugai Pharmaceutical
7.12. MedImmune LLC
7.13. RemeGen, Ltd.

List of Figures

FIG. 1 Devic’s Syndrome Treatment (DST): Market Segmentation
FIG. 2 Global DST Market Share, by Type of Drugs, 2018 (US$ Mn)
FIG. 3 Global DST Market, by Geography, 2018 Vs 2027 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2018
FIG. 5 Market Competition Landscape, by Key Players, 2018
FIG. 6 Global Eculizumab Market for DST, 2017 – 2027 (US$ Mn)
FIG. 7 Global Methylprednisolone Market for DST, 2017 – 2027 (US$ Mn)
FIG. 8 Global Azathioprine Market for DST, 2017 – 2027 (US$ Mn)
FIG. 9 Global Mycophenolate Mofetil Market for DST, 2017 – 2027 (US$ Mn)
FIG. 10 Global Rituximab Market for DST, 2017 – 2027 (US$ Mn)
FIG. 11 Global Satralizumab Market for DST, Till 2027 (US$ Mn)
FIG. 12 Global MEDI-551 Market for DST, Till 2027 (US$ Mn)
FIG. 13 Global RC18 Market for DST, Till 2027 (US$ Mn)
FIG. 14 U.S. DST Market, 2017 – 2027 (US$ Mn)
FIG. 15 Canada DST Market, 2017 – 2027 (US$ Mn)
FIG. 16 U.K. DST Market, 2017 – 2027 (US$ Mn)
FIG. 17 Germany DST Market, 2017 – 2027 (US$ Mn)
FIG. 18 Rest Of Europe DST Market, 2017 – 2027 (US$ Mn)
FIG. 19 Japan DST Market, 2017 – 2027 (US$ Mn)
FIG. 20 China DST Market, 2017 – 2027 (US$ Mn)
FIG. 21 Rest Of Asia Pacific DST Market, 2017 – 2027 (US$ Mn)
FIG. 22 Brazil DST Market, 2017 – 2027 (US$ Mn)
FIG. 23 Mexico DST Market, 2017 – 2027 (US$ Mn)
FIG. 24 Rest Of Latin America DST Market, 2017 – 2027 (US$ Mn)
FIG. 25 GCC DST Market, 2017 – 2027 (US$ Mn)
FIG. 26 Rest Of Middle East And Africa DST Market, 2017 – 2027 (US$ Mn)

List of Tables

TABLE 1 Global Devic’s Syndrome Treatment (DST) Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 2 North America DST Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 3 North America DST Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 4 Europe DST Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 5 Europe DST Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 6 Asia Pacific DST Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 7 Asia Pacific DST Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 8 Latin America DST Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 9 Latin America DST Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 Middle East & Africa DST Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 11 Middle East And Africa DST Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 12 Alexion Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 13 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 Fresenius Kabi AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Pharmacia & Upjohn (a subsidary of Pfizer): Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Lupin Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Sagent Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Zydus Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Sandoz Inc. (a subsidiary of Novartis): Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Alkem Laboratories Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Mylan Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Chugai Pharmaceutical Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 MedImmune LLC: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 RemeGen, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)